Use of somatostatin analog in management of carcinoid syndrome

Davis Z, Moertel CG, Mclirath DC: The malignant carcinoid syndrome. Surg Gynec Obstet 137:637–644, 1973 Buchanan KD, Johnston CF, O'Hare MMT, et al: Neuroendocrine tumors. A European view. Am J Med 81 (Suppl 6b): 14–22, 1986 Solcia E, Capella C, Buffa R, Frigerio B, Usellini L, Fiocca R: Morphological and functional classification of endocrine cells and related growths in the gastrointestinal tract.In Gastrointestinal Hormones. GBJ Glass (ed). New York, Raven Press, 1988, pp 1–17. Weil C: Gastroenteropancreatic endocrine tumors. Klivo 63:433–459, 1985 Simpson S, Vinik AI, Marangos PJ, Lloyd RV: Immunohistochemical localization of neuron-specific enolase in gastroentero-pancreatic neuroendocrine tumors. Correlation with tissue and serum levels of neuron-specific enolase. Cancer 54:1364, 1984 Moertel CG: Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol 1:727–740, 1983 Godwin JD II: Carcinoid tumors an analysis of 2837 cases. Cancer 36:560–569, 1975 Strodel W, Vinik A, Thompson N, et al: Carcinoid tumors of the small intestine.In Endocrine Surgery Update. NW Thompson, AI Vinik (eds). New York, Grune & Stratton, 1983, pp 293–320 Melmon KL, Sjoerdsma A, Oates JA, Laster L: Treatment of malabsorption and diarrhea of carcinoid syndrome with methysergide. Gastroenterology 48:18, 1965 Feldman JM: Urinary serotonin in the diagnosis of carcinoid tumor. Clin Chem 32:840–844, 1986 Sandler M, Karim SMM, William ED: Prostaglandin in amine-peptide-secreting tumors. Lancet 2:1053–1055, 1968 Alumets J, Hakanson R, Ingemannson S, Sundler F: Substance P and 5-HT in granules isolated from an intestinal argentaffin carcinoid. Histochemistry 52:217, 1977 Oates JA, Pettinger WA, Doctor RB: Evidence for the release of bradykinin in the carcinoid syndrome. J Clin Invest 45:173–178, 1966 Pernow B, Waidenstrom J: Determination of 5-hydroxytryptamine, 5 hydrosyindolacetic acid and histamine in thirtythree cases of carcinoid tumor (argentaffinoma). Am J Med 34:255–260, 1985 Wilander E, Grimelius L, Portela-Gomes G, Sloan JM: Substance P and enteroglucagon-like immunoreactivity in argentaffin and argyrophil mid gut carcinoid tumors. Scand J Gastroenterol (suppl) 14:19–25, 1979 Strodel WE, Vinik AI, Jaffe BM, Eckhauzer F, Thompson NW: Substance P in the localization of a carcinoid tumor. J Surg Oncol 27:106–111, 1984 Lucas KG, Feldman JM: Flushing in the carcinoid syndrome and plasma kallikrein. Cancer 58:2290–2293, 1986 Pernow B, Waldenstrom J: Determination of 5-hydroxytryptamine, 5-hydroxy indoleacetic acid and histamine in 33 cases of carcinoid (argentaffinoma). Am J Med 23:16–25, 1957 Feldman JM: Increased dopamine production in patients with carcinoid tumors. Metabolism 34:255–260, 1985 Theodrosson-Norheim E, Norheism KO, Brodin E, et al: Neuropeptide K: A major tachykinin in plasma and tumor tissues from carcinoid patients. Biochem Biophys Res Commun 131:77–83, 1985 Vinik AI, Strodel WM, Lloyd RV: Unusual gastroenteropancreatic tumors and their hormones.In Endocrine Surgery Update. NW Thompson, AI Vinik (eds). New York, Grune & Stratton, 1983, pp 293–320 Feldman J, O'Dorisio TM: Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors. Am J Med 81(suppl 6b):41–48, 1986 Kvols LK: Metastatic carcinoid tumors and the carcinoid syndrome. A selective review of chemotherapy and hormonal therapy. Am J Med 81 (suppl 6b):49–55, 1986 Maton PN, Camilleri M, Griffin G, Hodgson H, Allison DJ, Chadwick VS: The role of hepatic arterial embolization in the carcinoid syndrome. Br Med J 287:932–935, 1983 Gyn NE, Kayasseh L, Keller IJ: VIP and watery diarrhea.In Gut Hormones, 2nd ed. SR Bloom, JM Polak (ed). Edinburgh, Churchill Livinston, 1981, pp 581–585 Sheppard M, Shapiro B, Primstone B, Kronhein S, Berelowitz M, Gregory M: Metabolic clearance and plasma half-disappearance time of exogenous somatostatin in man. J Clin Endocrinol Metab 48:50–53, 1979 Bauer W, Briner U, Doepfner W, Waller R, Huguenin R, Marbach P, Fletcher TJ, Pless T: A very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 31:1133–1140, 1982 Walker TP: The determination of serotonin (5-hydroytryptamine) in human blood. J Lab Clin Med 55:824–829, 1959 Davis RB: The concentration of serotonin in normal human serum as determined by an improved method. J Lab Clin Med 54:344–351, 1959 Das ML: A rapid, sensitive method for direct estimation of serotonin in whole blood. Biochem Med 6:299–309, 1972 Udenfriend C, Titus E, Weissbach H: The identification of 5-hydroxy-3-indoleacetic acid in normal urine and a method for its assay. J Biol Chem 216:499–505, 1955 Vinik AI, Achem Karam S, Owyang C: Gastrointestinal hormones in clinical medicine.In Special Topics in Endocrinology and Metabolism, Vol 4. MP Cohen, PP Foa (eds). New York. Alan R. Liss, 1982, pp 93–138 Tsai ST, Lewis E, Vinik AI: The use of a somatostatin analogue in the management of the flushing syndrome. Scand J Gastroenterol 21(suppl 119):267–274, 1985 Frohlich J, Bloomgarden Z, Oates J, et al: The carcinoid flush provocation by pentagastrin and inhibition by somatostatin. N Engl J Med 299:1055–1057, 1978 Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J, Hahn R: Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 315:663–666, 1986 Richter G, Stockmann F, Lembeke B, Conlon JM, Creutzfeldt W: Short-term administration of somatostatin analogue SMS 20-1995 in patients with carcinoid tumors. Scand J Gastroenterol 21(suppl 119):193–198, 1986 Kvols LK, Martin JK, Marsh HM, Moertel CG: Carcinoid crisis: Rapid reversal of the life-threatening hypotension with a somatostatin analogue. N Engl J Med 313:1229, 1985 Santangelo WC, O'Dorisio TM, Kim JG, Severino G, Krejs GJ: Pancreatic cholera syndrome—effect of a synthetic somatostatin analogue on intestinal water and ion transport. Ann Intern Med 103:363–367, 1985 Vinik A, Tsai S, Moattarri A, Cheung P, Eckhauser F, Cho K: Somatostatin analogue (SMS 201-995) in the management of gastroenteropancreatic tumors and diarrhea syndromes. Am J Med 81(suppl 6b):23–40, 1986 Arnold R, Lankisch: Somatostatin and the gastrointestinal tract. Clin Gastroenterol 9:733–754, 1980 Stockmann F, Richter G, Lembcke B, Conlon JM, Creutzfeldt W: Long-term treatment of patients with endocrine gastrointestinal tumors with the somatostatin analogue SMS 201-995. Scand J Gastroenterol 21 (suppl 119):230–237, 1986 Hengl G, Prager J, Pointner H: The influence of somatostatin on the absorption of triglycerides in partially gastrectomized subjects. Acta Hepato-Gastroenterol 26:392–395, 1979 Wood SM, Kraenzlin ME, Adrian TE, Bloom SR: Treatment of patients with pancreatic endocrine tumors using a new long-acting somatostatin analogue: Symptomatic and peptide responses. Gut 26:438–444, 1985 Poole CJM: Myelopathy secondary to metastatic carcinoid tumors. J Neurol Neurosurg Psychiatr 47:1359–1360, 1984 Berry EM, Maunder C, Wilson M: Carcinoid myopathy and treatment with cyproheptadine (periactin). Gut 15:34–38, 1974 Green D, Joynt RJ, Van Allen MW: Neuromyopathy associated with a malignant carcinoid tumor. Arch Intern Med 114:494–496, 1964 Wroe SJ, Ardon M, Bouden AR: Myasthenia gravis associated with a hormone producing malignant carcinoid tumor. J Neurol Neurosurg Psychiat 48:719–720, 1985 O'Stern WK, Barnard JL Jr, Yates RD: Morphologic changes in skeletal muscle induced by serotonin treatment, a light and electron microscopy study. Exp Mol Pathol 7:145–155, 1967 Kraenzlin ME, Ching KC, Wood SM, Carr DH, Bloom SR: Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Gastorenterology 88:185–7, 1985